Trial Profile
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions
- Sponsors Bayer
- 03 Mar 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2024.
- 14 Jan 2022 Planned End Date changed from 31 May 2022 to 30 Jun 2023.
- 14 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.